ARCT - Arcturus gets Singapore regulatory greenlight for STARR mRNA vaccine trials

Arcturus Therapeutics (NASDAQ:ARCT) has received approval for a Clinical Trial Application (CTA) from the Singapore Health Sciences Authority (HSA) to enable the advancement of two STARR mRNA vaccine candidates into the clinic. Shares of the company up nearly 7% premarket. The Phase 1/2 clinical trial will evaluate the vaccines both as a primary vaccination series and as a booster following initial vaccination with Pfizer and BioNTech's Comirnaty. ARCT-154 and ARCT-165 are next generation STARR mRNA vaccine candidates targeting current SARS-CoV-2 variants of concern. Preclinical data demonstrated that ARCT-154 and ARCT-165 induce strong neutralizing immunogenicity in non-human primates to SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants, the company said.

For further details see:

Arcturus gets Singapore regulatory greenlight for STARR mRNA vaccine trials